Karen Posey

Dr. Karen Posey

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Matrix Biology
Verified
Journal Article
Closed access
KPKaren Posey
Karen Posey
FCFrancoise Coustry
Francoise Coustry
JHJacqueline T. Hecht
Jacqueline T. Hecht

9 April 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
KPKaren Posey
Karen Posey
FCFrancoise Coustry
Francoise Coustry
AVAlka C. Veerisetty
Alka C. Veerisetty
MHMohammad Hossain
Mohammad Hossain
JAJoseph L. Alcorn
Joseph L. Alcorn
JHJacqueline T. Hecht
Jacqueline T. Hecht
Pseudoachondroplasia (PSACH), a severe short-limb dwarfing condition, results from mutations that cause misfolding of the cartilage oligomeric matrix protein (COMP). Accumulated COMP in growth plate chondrocytes activates endoplasmic reticulum stress, leading to inflammation and chondrocyte death. Using a MT-COMP mouse model of PSACH that recapitulates the molecular and clinical PSACH phenotype, we previously reported that oxidative stress and inflammation play important and unappreciated roles in PSACH pathology. In this study, we assessed the ability of antioxidant and anti-inflammatory agents to affect skeletal and cellular pathology in our mouse model of PSACH. Treatment of MT-COMP mice with aspirin or resveratrol from birth to P28 decreased mutant COMP intracellular retention and chondrocyte cell death, and restored chondrocyte proliferation. Inflammatory markers associated with cartilage degradation and eosinophils were present in the joints of untreated juvenile MT-COMP mice, but were undetectable in treated mice. Most importantly, these treatments resulted in significantly increased femur length. This is the first and only therapeutic approach shown to mitigate both the chondrocyte and long-bone pathology of PSACH in a mouse model and suggests that reducing inflammation and oxidative stress early in the disease process may be a novel approach to treat this disorder.

1 July 2014 in Matrix Biology
Verified
Journal Article
Open access
KPKaren Posey
Karen Posey
JAJoseph L. Alcorn
Joseph L. Alcorn
JHJacqueline T. Hecht
Jacqueline T. Hecht
Pseudoachondroplasia (PSACH) is a skeletal dysplasia characterized by disproportionate short stature, small hands and feet, abnormal joints and early onset osteoarthritis. PSACH is caused by mutations in thrombospondin-5 (TSP-5, also known as cartilage oligomeric matrix protein or COMP), a pentameric extracellular matrix protein primarily expressed in chondrocytes and musculoskeletal tissues. The thrombospondin gene family is composed of matricellular proteins that associate with the extracellular matrix (ECM) and regulate processes in the matrix. Mutations in COMP interfere with calcium-binding, protein conformation and export to the extracellular matrix, resulting in inappropriate intracellular COMP retention. This accumulation of misfolded protein is cytotoxic and triggers premature death of chondrocytes during linear bone growth, leading to shortened long bones. Both in vitro and in vivo models have been employed to study the molecular processes underlying development of the PSACH pathology. Here, we compare the strengths and weaknesses of current mouse models of PSACH and discuss how the resulting phenotypes may be translated to clinical therapies.

1 September 2021 in The American Journal of Pathology
Verified
Journal Article
Closed access
JHJacqueline T. Hecht
Jacqueline T. Hecht
AVAlka C. Veerisetty
Alka C. Veerisetty
JWJuliana Wu
Juliana Wu
FCFrancoise Coustry
Francoise Coustry
MHMohammad G. Hossain
Mohammad G. Hossain
KPKaren Posey
Karen Posey

6 November 2013 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
KPKaren Posey
Karen Posey
FCFrancoise Coustry
Francoise Coustry
AVAlka C Veerisetty
Alka C Veerisetty
PLPeiman Liu
Peiman Liu
JAJoseph L Alcorn
Joseph L Alcorn
JHJacqueline T Hecht
Jacqueline T Hecht
: Mutations in the gene encoding cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia (PSACH), a severe dwarfing condition. Pain, a significant complication, has generally been attributed to joint abnormalities and erosion and early onset osteoarthritis. Previously, we found that the inflammatory-related transcripts were elevated in growth plate and articular cartilages, indicating that inflammation plays an important role in the chondrocyte disease pathology and may contribute to the overall pain sequelae. Here, we describe the effects of D469-delCOMP expression on the skeleton and growth plate chondrocytes with the aim to define a treatment window and thereby reduce pain. Consistent with the human PSACH phenotype, skeletal development of D469del-COMP mice was normal and similar to controls at birth. By postnatal day 7 (P7), the D469del-COMP skeleton, limbs, skull and snout were reduced and this reduction was progressive during postnatal growth, resulting in a short-limbed dwarfed mouse. Modulation of prenatal and postnatal expression of D469del-COMP showed minimal retention/cell death at P7 with some retention/cell death by P14, suggesting that earlier treatment intervention at the time of PSACH diagnosis may produce optimal results. Important and novel findings were an increase in inflammatory proteins generally starting at P21 and that exercise exacerbates inflammation. These observations suggest that pain in PSACH may be related to an intrinsic inflammatory process that can be treated symptomatically and is not related to early joint erosion. We also show that genetic ablation of CHOP dampens the inflammatory response observed in mice expressing D469del-COMP. Toward identifying potential treatments, drugs known to decrease cellular stress (lithium, phenylbutyric acid, and valproate) were assessed. Interestingly, all diminished the chondrocyte pathology but had untoward outcomes on mouse growth, development, and longevity. Collectively, these results define an early treatment window in which chondrocytes can be salvaged, thereby potentially increasing skeletal growth and decreasing pain. © 2014 American Society for Bone and Mineral Research.

1 September 2017 in Bone
Verified
Journal Article
Closed access
KPKaren Posey
Karen Posey
JHJacqueline T. Hecht
Jacqueline T. Hecht